The Pharma Data

OCTOBER 20, 2020

MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development. Earlier in his career, he ran business-development functions at Amgen and Baxter.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

The Pharma Data

JUNE 7, 2023

LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

NOVEMBER 25, 2020

Shafi Khan , Burkhan World’s VP of Business Development stated, “Burkhan is honoured to have partnered up with Vivera in supporting its efforts globally in the medical supply sector. With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. ,

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Manufacturing Licensing 52

The Pharma Data

OCTOBER 27, 2020

With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas.

Sales 52

Sales Production Drug Delivery Development 52

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Simone Oostindie, PhD, Director, Research and Discovery, Gyes, on: ‘Avidity engineering: A next frontier in the development of differentiating antibody therapeutics’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40